Study Design Reference
Country
Study population
No. of patients* (AKI/Overall) Incidence* (%) Age (Mean/Median) Biopsy-confirmed diagnosis (n) Recovery (%) Retreatment (%)
Retrospective13 Romania Patients under anti-TB treatment (outcome only in retreatment group) 55/120,132 0.05 45 ATIN (4), ATN (1) 96 100
Retrospective8 Worldwide AKI after rifampin 48/NA NA 47.4 ATIN (4), ATN (11), crescentic GN (2) 87 64
Retrospective16 India Rifampin-associated AKI 25/NA NA 41.6 ATIN (7), ATN (2), crescentic GN (1), mesangial proliferation (3) 100 80
Retrospective15 South Africa Biopsy-proven AIN under anti-TB treatment 41/NA NA 42.2 ATIN (41) 83 83
Retrospective14 Taiwan Patients under anti-TB treatment 99/1,394 7.1 68 NA 73 11
Prospective (current study) Taiwan Patients under anti-TB treatment 11/106 10.4 52.6 NA 100 2.8